Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting

• US 20110135724A1
• Filed: 11/30/2010
• Published: 06/09/2011
• Est. Priority Date: 11/30/2009
• Status: Abandoned Application

• Current Assignee: Aptalis Pharmatech Incorporated
• Original Assignee: Eurand Incorporated (Abbvie Incorporated)
• Inventors: Venkatesh, Gopi M.
• Application Number:
  US12/956,249
• Publication Number:
  US 20110135724A1
• Time in Patent Office: Days
• US Class Current: 424/465
• CPC Class Codes: A61K 31/4178 not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• CPC Class Codes: A61K 9/0056 Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/2081 with microcapsules or coated microparticles according to A61K9/50
• CPC Class Codes: A61K 9/5026 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics

Abstract

This invention is related to a pharmaceutical composition in the patient-friendly orally disintegrating tablet form comprising a weakly basic, selective serotonin 5-HT₃ blocking agent for the prevention of nausea and/or vomiting for up to 24 hrs postdosing in cancer patients prior to undergoing moderately emetogenic chemotherapy or partial or whole body radiotherapy or in subjects at moderate to high risk of postoperative or postdischarge nausea and/or vomiting prior to inpatient or outpatient ambulatory surgery. The unit dosage form comprising a multitude of immediate-release drug particles providing dissolution profiles similar to that of reference drug product, and one or more timed, pulsatile-release bead populations, comprising at least one organic acid, which solubilizes said weakly basic selective serotonin 5-HT₃ blocking agent prior to releasing it into the hostile intestinal environment, wherein the blocking agent is practically insoluble, is capable of delivering said antiemetic agent in patients in need thereof in a sustained-released fashion to be suitable for a once-daily dosing regimen.

Claims

1. An ODT comprising:

at least one population of taste-masked immediate-release (IR) drug microparticles comprising a selective serotonin 5-HT₃ blocking agent, wherein the taste-masked IR microparticles provide dissolution profiles similar to that of a reference drug product;

at least one population of timed, pulsatile release (TPR) beads comprising the selective serotonin 5-HT₃ blocking agent and at least one pharmaceutically acceptable organic acid, wherein the organic acid is not depleted from the TPR beads until completion of the drug release from the dosage form when dissolution tested by United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2—

paddles@ 50 RPM and a two-stage dissolution medium at 37°

C. (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8); and

rapidly dispersing microgranules comprising at least one super disintegrant and at least one sugar alcohol, a saccharide, or a mixture thereof

2. The ODT of claim 1, wherein the rapidly dispersing microgranules and the taste-masked IR microparticles and TPR beads have a mean particle size of less than about 400 μ

m.

3. The ODT of claim 1 wherein:

the taste-masked IR microparticles have an average particle size of less than 400 μ

m, and are taste-masked with a taste-masking membrane comprising a water-insoluble polymer;

the TPR beads comprise an outer lag-time coating comprising a water-insoluble polymer in combination with an enteric polymer disposed over immediate release selective serotonin 5-HT₃ blocking agent-containing beads, said outer lag-time coating providing a lag time of from about 2 to about 4 hours before onset of drug release when dissolution tested by United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2—

paddles@ 50 RPM and a two-stage dissolution medium at 37°

C. (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8);

wherein the immediate release selective serotonin 5-HT₃ blocking agent-containing beads comprise at least one selective serotonin 5-HT₃ blocking agent disposed over an SR- or TPR-coated organic acid core particle;

said SR- or TPR-coated organic acid core particle comprises an inner barrier coating disposed over an organic acid core particle, said inner barrier coating comprising a water-insoluble polymer alone or in combination with a water-soluble or enterosoluble polymer and providing a sustained-release profile of said organic acid; and

said organic acid core particle comprises at least one pharmaceutically acceptable organic acid.

4. The ODT of claim 3, wherein the taste-masking membrane disposed on the IR microparticle further comprises a gastrosoluble pore-forming agent, wherein the ratio of water-insoluble polymer to gastrosoluble pore-forming agent varies from about 9:

1 to 1;

1.

5. The ODT of claim 4, wherein the gastrosoluble pore-forming agent is selected from the group consisting of calcium carbonate, calcium phosphate, calcium saccharide, calcium succinate, calcium tartrate, ferric acetate, ferric hydroxide, ferric phosphate, magnesium carbonate, magnesium citrate, magnesium hydroxide, magnesium phosphate, and mixtures thereof

6. The ODT of claim 4, wherein the taste-masking membrane comprises water-insoluble ethylcellulose and a gastrosoluble polymer at a ratio of from about 9:

1 to 1;

1, and is disposed on the IR microparticle at a coating weight of from about 5% to 40% based on the weight of the taste-masked IR microparticle.

7. The ODT of claim 1, comprising rapidly-dispersing microgranules with an average particle size of not more than 400 μ

m, wherein the super disintegrant and sugar alcohol or saccharide or combination thereof, each have an average particle size of not more than about 30 μ

m;

wherein the ODT exhibits the following properties;

a friability of less than 1% by weight; and

a disintegration time of about 60 seconds or less on contact with the saliva in the oral cavity, wherein after disintegration in the oral cavity, the ODT forms a smooth suspension.

8. The ODT of claim 1, wherein the ratio of rapidly dispersing microgranules to the total amount of taste-masked IR microparticles and TPR beads ranges from about 4:

1 to 1;

1, thereby providing a smooth mouthfeel in patients in need of said medication.

9. The ODT of claim 1, wherein the ODT rapidly disintegrates on contact with the saliva in the oral cavity of a patient, thereby forming a smooth (non-gritty), easy-to-swallow suspension comprising taste-masked IR microparticles and TPR beads that are easily swallowed by patients with or without having difficulty in swallowing tablets or capsules.

10. The ODT of claim 1, wherein the ratio of the selective serotonin 5-HT₃ blocking agent in the taste-masked IR microparticles to the total amount of selective serotonin 5-HT₃ blocking agent in the TPR beads varies from about 20:

80 to about 60;

40.

11. The ODT of claim 1, further comprising at least one water soluble excipient;

wherein the taste-masked IR drug particles comprise an inert core selected from the group consisting of a sugar sphere, cellulosic sphere, cellulose-lactose, cellulose-mannitol, and fused silicon dioxide spheres or granules, layered with the selective serotonin 5-HT₃ blocking agent, and coated with a taste-masking membrane comprising said drug; and

wherein the ratio of the selective serotonin 5-HT₃ blocking agent in the taste-masked IR microparticles to the total amount of selective serotonin blocking agent in the TPR beads varies from about 20;

80 to about 60;

40.

12. The ODT of claim 1, wherein said weakly basic selective serotonin 5-HT₃ blocking agent is selected from the group consisting of ondansetron, tropisetron, granisetron, dolasetron, palonosetron, ramosetron, and pharmaceutically acceptable salts and/or solvates thereof.

13. The ODT of claim 1, wherein the organic acid is selected from the group consisting of citric acid, fumaric acid, malic acid, maleic acid, tartaric acid, succinic acid, oxalic acid, aspartic acid, glutamic acid and mixtures thereof.

14. The ODT of claim 1, wherein the ratio of selective serotonin 5-HT₃ blocking agent to organic acid varies from about 5:

1 to 1;

10 by weight, and provides a pharmacokinetic profile suitable for a once-daily dosing regimen.

15. The ODT of claim 1, wherein the selective serotonin 5-HT₃ blocking agent is ondansetron or a pharmaceutically acceptable salt and/or a solvate thereof and the organic acid is fumaric acid.

16. The ODT of claim 1, wherein the TPR beads comprise an organic acid core particle coated with the selective serotonin 5-HT₃ blocking agent;

wherein the organic acid core particle is selected from the group consisting of;

an organic acid crystal;

an inert particle coated with an organic acid and a polymeric binder; and

a pellet containing the organic acid, a polymeric binder and a diluent/filler, prepared by controlled spheronization using a Vector Granurex X-35 or equivalents thereof, a rotogranulator from Glatt or equivalents thereof, or by granulation-extrusion-spheronization.

17. The ODT of claim 1, wherein the TPR beads comprise an organic acid core particle comprising the organic acid, a barrier coating disposed over the organic acid, and the selective serotonin 5-HT₃ blocking agent disposed over the barrier coating;

wherein the barrier coating comprises a water-insoluble polymer optionally in combination with a water-soluble or enteric polymer at a ratio of from about 9;

1 to 5;

5, and wherein the barrier coating is applied at a coating weight of from about 5% to 40% based on the weight of the TPR bead; and

further comprising an outer lag-time coating disposed over the selective serotonin 5-HT₃ blocking agent, wherein the outer lag-time coating comprises a water-insoluble polymer in combination with an enteric polymer.

18. The ODT of claim 17, wherein the barrier coating comprises the combination of a water-insoluble polymer and a water-soluble polymer selected from the group consisting of methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone and polyethylene glycol and mixtures thereof.

19. The ODT of claim 3, 4, or 17, wherein the taste-masking membrane comprises a water-insoluble polymer selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylic acid-methylmethacrylate copolymers, and mixtures thereof.

20. The ODT of claim 3 or 17, wherein the enteric polymer of the TPR beads is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose succinate, polyvinyl acetate phthalate, pH-sensitive methacrylic acid-methylmethacrylate copolymers, shellac, derivatives thereof, and mixtures thereof.

21. The ODT of claim 16, wherein the organic acid core particle is an inert particle coated with an aorganic acid and a polymeric binder, wherein the polymeric binder is selected from the group consisting of methylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinyl pyrrolidone and polyethylene glycol and mixtures thereof.

22. The ODT of claim 3, wherein the lag-time coating of the TPR beads comprises water-insoluble ethylcellulose in combination with enteric hypromellose phthalate at a ratio of from about 9:

1 to 1;

3, respectively, for a coating weight of from about 10% to 60% based on the weight of the TPR beads.

23. The ODT of claim 3, wherein one or more of said taste-masking membrane, said inner barrier coating, and said lag-time coating independently further comprises a plasticizer selected from the group consisting of triacetin, tributyl citrate, tri-ethyl citrate, acetyl tri-n-butyl citrate, diethyl phthalate, dibutyl sebacate, polyethylene glycol, polypropylene glycol, castor oil, acetylated mono- and di-glycerides and mixtures thereof.

24. The ODT of claim 1, wherein said IR microparticles provide a loading dose by releasing not less than about 85% of the selective serotonin 5-HT₃ blocking agent contained in the taste-masked IR microparticles within 30 minutes under in vitro dissolution conditions.

25. The ODT of claim 1, wherein the composition substantially disintegrates within about 60 seconds after administration in the oral cavity of the patient.

26. The ODT of claim 1, wherein said composition disintegrates within about 30 seconds when tested by the <

USP 701>

Disintegration Test.

27. The ODT of claim 1, further comprising other pharmaceutically acceptable excipients selected from the group consisting of a flavor, a sweetener, additional disintegrant and a diluent, and the ODT disintegrates in the oral cavity in about 60 seconds creating a smooth, easy-to-swallow suspension of multi-coated beads which provide target pharmacokinetics profiles suitable for a once-daily dosing regimen in patients in need of such a medication.

28. The ODT composition of claim 1, wherein said taste-masked IR microparticles and said TPR beads further comprise a compressible coating applied on individual drug particles to eliminate/minimize potential fracture of the coating membrane during compression into ODT tablets.

33. A method of treating or preventing postoperative nausea and vomiting or postdischarge nausea and vomiting for up to 24 hours post-dosing, comprising orally administering to a surgical patient in need thereof, at least one ODT of claim 1, prior to and/or after surgery and optionally once-daily for up to 4 additional days.

34. A method of treating or preventing nausea and vomiting for up to 24 hours post-dosing, comprising orally administering to a cancer patient in need thereof, at least one ODT tablet of claim 1, prior to undergoing moderately emetogenic cancer chemotherapy and optionally once-daily for up to 2 additional days.

35. A method of treating or preventing nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen for up to 24 hours post-dosing, comprising orally administering to a cancer patient in need thereof, at least one ODT tablet of claim 1 prior to radiotherapy and optionally once-daily for up to 2 additional days.

29. A method for the preparation of a multiparticulate ODT tablet comprising a selective serotonin 5-HT₃ blocking agent, and at least one pharmaceutically acceptable organic acid, comprising the steps of:

preparing rapidly releasing selective serotonin 5-HT₃ blocking agent-containing immediate release (IR) microparticles;

applying a taste-masking membrane comprising a water-insoluble polymer or a water-insoluble polymer in combination with a gastrosoluble pore-forming agent, over the IR microparticles;

preparing organic acid cores;

coating the organic acid cores with an SR or TPR coating comprising a water-insoluble polymer alone or a water-insoluble polymer in combination with a water-soluble polymer or an enteric polymer at a ratio of from about 95;

5 to about 50;

50 for a coating weight of up to about 30%, to provide a sustained-release profile;

layering the selective serotonin 5-HT₃ blocking agent or pharmaceutically acceptable salt thereof from a polymer binder solution onto the SR- or TPR-coated organic acid cores and optionally applying a protective seal-coat with a water-soluble polymer;

optionally applying a barrier (SR) coating of a water-insoluble polymer, or a water-insoluble polymer in combination with a water-soluble polymer at a ratio of from about 95;

5 to about 50;

50 to the selective serotonin 5-HT₃ blocking agent layered beads for a weight gain of from about 1.5% to 20% by dry weight of the coated IR beads;

applying an outer lag-time coating to the selective serotonin 5-HT₃ blocking agent layered beads, wherein the outer lag-time coating comprises a water-insoluble polymer in combination with an enteric polymer at a ratio of from about 9;

1 to 1;

3 for a weight gain of from about 10% to 60% by weight of the coated bead; and

preparing rapidly dispersing microgranules comprising a super disintegrant, at least one sugar alcohol, a saccharide, or a mixture thereof, each primary particle having an average particle size of not more than 30 μ

m by high shear granulation and fluid bed drying or tray drying;

blending/compressing appropriate amounts of each of rapidly dispersing microgranules, taste-masked IR microparticles, TPR beads, and other pharmaceutically acceptable excipients, into ODT tablets.

30. The method of claim 29, wherein said compressing is with an external lubrication system for externally lubricating dies and punches prior to each compression

31. The method of claim 29, wherein each of said SR- or TPR-coating, drug-layering and outer lag-time coating is applied from a solution in a pharmaceutically acceptable solvent system or from an aqueous dispersion.

32. The method of claim 29 wherein the ODT comprises therapeutically effective amounts of a weakly basic, selective serotonin 5-HT₃ blocking agent as taste-masked IR drug beads and one or more TPR bead populations, said TPR bead population exhibiting differing release characteristics following a pre-determined lag-time.

36. The method of claim 29, wherein the selective serotonin 5-HT₃ blocking agent is ondansetron or pharmaceutically acceptable salts and/or solvates thereof, in an amount equivalent to 16 to 24 mg of ondansetron as base.